Thomas K. Karikari

This paper introduces SPEAR, a separation-free protein detection method that achieves sub-100-molecule sensitivity using engineered kinetic proofreading, outperforming existing methods for Alzheimer's and SARS-CoV-2 biomarkers.

This study evaluates harmonization methods to reduce assay and cohort effects in plasma p-tau217 measurements across two cohorts, finding that quantile mapping is most effective.

The paper examines the relationship between cardiometabolic factors, blood beta-amyloid, and white matter hyperintensities in dementia-free individuals with cognitive complaints, finding stronger associations with cardiometabolic markers.

The paper investigates GFAP-positive astrocyte responses to amyloid-beta and tau pathologies in humans and mouse models, finding distinct molecular signatures associated with each pathology.

The paper develops a personalized brain activity model integrating functional MRI, Aβ, and tau-PET to reveal synergistic effects of Aβ and tau on cognitive impairment and neuronal excitability in Alzheimer's disease.

This study investigates the effects of cerebrospinal fluid tau on neuronal function using electrophysiological recordings in mouse brain slices.

The paper examines the effect of APOE ε4 gene dose on glial reactivity and β-amyloid pathology in cognitively unimpaired individuals using PET, MRI, and plasma biomarkers.

The paper shows that MEG3, a long noncoding RNA, induces necroptosis in human neurons exposed to amyloid pathology, mimicking AD features in a xenograft model.

The paper investigates how different regions of the tau protein affect neuronal function by truncating tau and analyzing its effects on voltage-gated sodium channels.